Analyst Viewpoint
Increase in incidence of thrombotic disorders and advancements in drug development are contributing to the thrombosis drugs market growth. Sedentary lifestyles, obesity, aging population, and chronic diseases are multiple factors boosting the demand for thrombosis drugs.
R&D of novel anti-clotting agents and antiplatelet agents with improved efficacy and safety profiles is fueling the thrombosis drugs market size. Awareness and early recognition of symptoms are critical in preventing life-threatening complications of thrombotic disorders.
Vendors are emphasizing the development of once-a-week dosing regimens to improve patient compliance, reduce treatment burden, and enhance quality of life for pediatric patients and their caregivers.
Thrombosis is a blood clot within blood vessels that limits the flow of blood. Venous thrombosis and arterial thrombosis are two main types of thrombosis. Venous thrombosis is also known as Deep Vein Thrombosis (DVT).
It is a condition that causes a blood clot in the affected area of the body. Arterial thrombosis is when the blood clot blocks an artery. Arteries carry oxygen-rich blood away from the heart to the body.
Thrombosis is caused by three factors: hypercoagulability, vascular endothelial injury in the blood vessel wall, and abnormal circulatory system. Hypercoagulability or thrombophilia is the increased tendency of blood to thrombose.
Vascular endothelial injury is a common and early event in cardiovascular disease (CVD) that happens when damage occurs to the vascular endothelium, the thin layer of cells that lines blood vessels. The abnormal circulatory system affects the heart and blood vessels and makes it harder for blood to flow throughout the body.
According to the CDC, the precise number of people affected by DVT or pulmonary embolism (PE) is unknown. However, as many as 900,000 people could be affected each year in the U.S. DVT is responsible for an increased mortality rate in elderly persons.
In the U.S., DVT is associated with a projected initial hospitalization cost of US$ 9,805. Daily mean expenditure accounts for US$ 1,594 for the initial episodes and an estimated annual cost for treatment ranging from US$ 4.9 Bn to US$ 7.5 Bn.
Thus, venous thromboembolism remains a significant problem today, which is propelling the thrombotic disorders fueling market value.Lower extremities deep venous thrombosis is one of the common complications of lower extremity trauma in elderly people.
Trauma, such as fractures or significant soft tissue injuries in the lower limbs, can disrupt the normal blood flow and increase the risk of blood clot formation in the veins. Surge in geriatric population is boosting the thrombosis drugs industry statistics.
By 2050, the world's population of people aged 60 years and older is projected to reach 2.1 billion, according to the World Health Organization. This phenomenon is going to be quite pronounced in Asia Pacific and Europe.
DVT and PE treatment generally involves anticoagulation, intravenous unfractionated heparin initially followed by long-term oral anticoagulation. The introduction of low–molecular weight heparin preparations (LMWHs) is revolutionizing acute treatment.
New oral anticoagulants employed for the treatment of thrombosis include selective, direct thrombin inhibitors, such as dabigatran etexilate, and selective, direct factor Xa inhibitors, including rivaroxaban, apixaban, or edoxaban.
Research and development of new drugs is augmenting the thrombosis drugs market revenue. In August 2023, a team of researchers from the University of Tokyo proposed a side effect–free anticoagulating treatment that has so far proved effective in test mice and could be ready for human trials in just a few years.
The team devised a potent thrombin inhibitor based on bivalent aptamers with a higher safety profile via combination with the antidote. Such anticoagulant aptamers can be used for heparin-induced thrombocytopenia treatment with a higher safety profile.
According to the thrombosis drugs market trends, the factor Xa inhibitor drug class segment dominated the industry in 2022, followed by the P2Y12 platelet inhibitor segment. Increase in preference for oral anticoagulant drugs with predictable dose release response is likely to propel the segment during the forecast period.
North America held major share in 2022. High utilization rate of new oral anticoagulant drugs is propelling the market dynamics in the region. Moreover, favorable reimbursement for the treatment of different thrombosis events under Medicare policy is also boosting the thrombosis drugs market share in North America.
Key thrombosis drug manufacturers are developing next-generation anticoagulants for managing thrombosis to meet the growth in demand for safer and more effective therapies.
GSK plc, Baxter International Inc., Johnson & Johnson, Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, Bayer AG, Aspen Pharmacare Holdings Limited, Boehringer Ingelheim GmbH, and Pfizer, Inc. are key players operating in this market.
The thrombosis drugs market report highlights these companies in terms of parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Value in 2022 (Base Year) | US$ 29.1 Bn |
| Market Forecast Value in 2031 | US$ 51.5 Bn |
| Growth Rate (CAGR) | 6.7% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon Request |
| Pricing | Available upon Request |
It was valued at US$ 29.1 Bn in 2022
It is projected to grow at a CAGR of 6.7% from 2023 to 2031
Increase in incidence of thrombotic disorders and advancements in drug development
North America was the most lucrative region in 2022
GSK plc, Baxter International Inc., Johnson & Johnson, Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, Bayer AG, Aspen Pharmacare Holdings Limited, Boehringer Ingelheim GmbH, and Pfizer, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Thrombosis Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Thrombosis Drugs Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Thrombosis Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. Factor Xa Inhibitor
6.3.2. Low Molecular Weight Heparin
6.3.3. P2Y12 Platelet Inhibitor
6.3.4. Others
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Thrombosis Drugs Market Analysis and Forecast, by Indication
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indication, 2017–2031
7.3.1. Pulmonary Embolism
7.3.2. Atrial Fibrillation
7.3.3. Deep Vein Thrombosis
7.3.4. Others
7.4. Market Attractiveness Analysis, by Indication
8. Global Thrombosis Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Thrombosis Drugs Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Thrombosis Drugs Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Drug Class, 2017–2031
10.3.1. Factor Xa Inhibitor
10.3.2. Low Molecular Weight Heparin
10.3.3. P2Y12 Platelet Inhibitor
10.3.4. Others
10.4. Market Value Forecast, by Indication, 2017–2031
10.4.1. Pulmonary Embolism
10.4.2. Atrial Fibrillation
10.4.3. Deep Vein Thrombosis
10.4.4. Others
10.5. Market Value Forecast, by Distribution Channel, 2017–2031
10.5.1. Hospital Pharmacies
10.5.2. Retail Pharmacies
10.5.3. Online Pharmacies
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Drug Class
10.7.2. By Indication
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Thrombosis Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Drug Class, 2017–2031
11.3.1. Factor Xa Inhibitor
11.3.2. Low Molecular Weight Heparin
11.3.3. P2Y12 Platelet Inhibitor
11.3.4. Others
11.4. Market Value Forecast, by Indication, 2017–2031
11.4.1. Pulmonary Embolism
11.4.2. Atrial Fibrillation
11.4.3. Deep Vein Thrombosis
11.4.4. Others
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Drug Class
11.7.2. By Indication
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Thrombosis Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Drug Class, 2017–2031
12.3.1. Factor Xa Inhibitor
12.3.2. Low Molecular Weight Heparin
12.3.3. P2Y12 Platelet Inhibitor
12.3.4. Others
12.4. Market Value Forecast, by Indication, 2017–2031
12.4.1. Pulmonary Embolism
12.4.2. Atrial Fibrillation
12.4.3. Deep Vein Thrombosis
12.4.4. Others
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Drug Class
12.7.2. By Indication
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Thrombosis Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Drug Class, 2017–2031
13.3.1. Factor Xa Inhibitor
13.3.2. Low Molecular Weight Heparin
13.3.3. P2Y12 Platelet Inhibitor
13.3.4. Others
13.4. Market Value Forecast, by Indication, 2017–2031
13.4.1. Pulmonary Embolism
13.4.2. Atrial Fibrillation
13.4.3. Deep Vein Thrombosis
13.4.4. Others
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Drug Class
13.7.2. By Indication
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Thrombosis Drugs Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Drug Class, 2017–2031
14.3.1. Factor Xa Inhibitor
14.3.2. Low Molecular Weight Heparin
14.3.3. P2Y12 Platelet Inhibitor
14.3.4. Others
14.4. Market Value Forecast, by Indication, 2017–2031
14.4.1. Pulmonary Embolism
14.4.2. Atrial Fibrillation
14.4.3. Deep Vein Thrombosis
14.4.4. Others
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Drug Class
14.7.2. By Indication
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. GSK plc
15.3.1.1. Company Overview
15.3.1.2. Product Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Baxter International Inc.
15.3.2.1. Company Overview
15.3.2.2. Product Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Johnson & Johnson
15.3.3.1. Company Overview
15.3.3.2. Product Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Sanofi
15.3.4.1. Company Overview
15.3.4.2. Product Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Bristol-Myers Squibb Company
15.3.5.1. Company Overview
15.3.5.2. Product Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. AstraZeneca plc
15.3.6.1. Company Overview
15.3.6.2. Product Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Bayer AG
15.3.7.1. Company Overview
15.3.7.2. Product Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Aspen Pharmacare Holdings Limited
15.3.8.1. Company Overview
15.3.8.2. Product Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Boehringer Ingelheim GmbH
15.3.9.1. Company Overview
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Pfizer, Inc.
15.3.10.1. Company Overview
15.3.10.2. Product Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
List of Tables
Table 01: Global Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 02: Global Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 03: Global Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 04: Global Thrombosis Drugs Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 07: North America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 08: North America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Thrombosis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 11: Europe Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 12: Europe Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Asia Pacific Thrombosis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 15: Asia Pacific Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 16: Asia Pacific Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: Latin America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 19: Latin America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 20: Latin America Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031
Table 23: Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Indication, 2017–2031
Table 24: Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Thrombosis Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2022–2031
Figure 02: Global Thrombosis Drugs Market Revenue (US$ Mn), by Drug Class, 2022
Figure 03: Global Thrombosis Drugs Market Value Share, by Drug Class, 2022
Figure 04: Global Thrombosis Drugs Market Revenue (US$ Mn), by Indication, 2022
Figure 05: Global Thrombosis Drugs Market Value Share, by Indication, 2022
Figure 06: Global Thrombosis Drugs Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 07: Global Thrombosis Drugs Market Value Share, by Distribution Channel, 2022
Figure 08: Global Thrombosis Drugs Market Value Share, by Region, 2022
Figure 09: Global Thrombosis Drugs Market Value (US$ Mn) Forecast, 2023–2031
Figure 10: Global Thrombosis Drugs Market Value Share Analysis, by Drug Class, 2022–2031
Figure 11: Global Thrombosis Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 12: Global Thrombosis Drugs Market Value Share Analysis, by Indication, 2022–2031
Figure 13: Global Thrombosis Drugs Market Attractiveness Analysis, by Indication, 2023–2031
Figure 14: Global Thrombosis Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 15: Global Thrombosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 16: Global Thrombosis Drugs Market Value Share Analysis, by Region, 2022–2031
Figure 17: Global Thrombosis Drugs Market Attractiveness Analysis, by Region, 2023–2031
Figure 18: North America Thrombosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 19: North America Thrombosis Drugs Market Attractiveness Analysis, by Country, 2023–2031
Figure 20: North America Thrombosis Drugs Market Value Share Analysis, by Country, 2022–2031
Figure 21: North America Thrombosis Drugs Market Value Share Analysis, by Drug Class, 2022–2031
Figure 22: North America Thrombosis Drugs Market Value Share Analysis, by Indication, 2022–2031
Figure 23: North America Thrombosis Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 24: North America Thrombosis Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 25: North America Thrombosis Drugs Market Attractiveness Analysis, by Indication, 2023–2031
Figure 26: North America Thrombosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 27: Europe Thrombosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 28: Europe Thrombosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 29: Europe Thrombosis Drugs Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 30: Europe Thrombosis Drugs Market Value Share Analysis, by Drug Class, 2022–2031
Figure 31: Europe Thrombosis Drugs Market Value Share Analysis, by Indication, 2022–2031
Figure 32: Europe Thrombosis Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 33: Europe Thrombosis Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 34: Europe Thrombosis Drugs Market Attractiveness Analysis, by Indication, 2023–2031
Figure 35: Europe Thrombosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 36: Asia Pacific Thrombosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 37: Asia Pacific Thrombosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 38: Asia Pacific Thrombosis Drugs Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 39: Asia Pacific Thrombosis Drugs Market Value Share Analysis, by Drug Class, 2022–2031
Figure 40: Asia Pacific Thrombosis Drugs Market Value Share Analysis, by Indication, 2022–2031
Figure 41: Asia Pacific Thrombosis Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 42: Asia Pacific Thrombosis Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 43: Asia Pacific Thrombosis Drugs Market Attractiveness Analysis, by Indication, 2023–2031
Figure 44: Asia Pacific Thrombosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 45: Latin America Thrombosis Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 46: Latin America Thrombosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 47: Latin America Thrombosis Drugs Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 48: Latin America Thrombosis Drugs Market Value Share Analysis, by Drug Class, 2022–2031
Figure 49: Latin America Thrombosis Drugs Market Value Share Analysis, by Indication, 2022–2031
Figure 50: Latin America Thrombosis Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 51: Latin America Thrombosis Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 52: Latin America Thrombosis Drugs Market Attractiveness Analysis, by Indication, 2023–2031
Figure 53: Latin America Thrombosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 54: Middle East & Africa Thrombosis Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 55: Middle East & Africa Thrombosis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 56: Middle East & Africa Thrombosis Drugs Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 57: Middle East & Africa Thrombosis Drugs Market Value Share Analysis, by Drug Class, 2022–2031
Figure 58: Middle East & Africa Thrombosis Drugs Market Value Share Analysis, by Indication, 2022–2031
Figure 59: Middle East & Africa Thrombosis Drugs Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 60: Middle East & Africa Thrombosis Drugs Market Attractiveness Analysis, by Drug Class, 2023–2031
Figure 61: Middle East & Africa Thrombosis Drugs Market Attractiveness Analysis, by Indication, 2023–2031
Figure 62: Middle East & Africa Thrombosis Drugs Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Thrombosis Drugs Market
*86 figures and 60 tables includes